site stats

Shoc2 inhibitor

Webwww.ncbi.nlm.nih.gov Web8 Sep 2024 · The cancer cells were either exposed to EGFR inhibitors only or to a combination of EGFR and SOS1 inhibitors. The most effective treatment was found to be through combinational therapy, with enhanced killing of drug-resistant cells. ... (2024) SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition …

Therapeutic potential of SHOC2 via its selective contribution of …

Web1 Jul 2024 · SHOC2 is a scaffolding protein that facilitates RAS signaling by binding to RAS, RAS effectors (RAF1/PI3K) and other downstream regulators. Based on our findings, we hypothesize that SHOC2 is a novel, potent target to sensitize KRAS mutant pancreatic cancer cells to MEK inhibitors through mechanisms downstream of RAS signaling. WebGlioblastoma multiforme (GBM) is an aggressive type of brain tumor where . 3% of newly diagnosed cases in the patients will survive >5 years.. In adults, GBM is the most common type of brain tumor. It is rarer in children, where it constitutes approximately 15% of all brain tumors diagnosed. nist 800-60 and reference table c-1 https://uptimesg.com

Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity …

Web5 Nov 2024 · The immunoprecipitates were analyzed by immunoblotting using anti-Ub and -Shoc2 antibodies. Cell lysates were analyzed using anti-USP7, -Ub and -Shoc2 antibodies. … Web4 Feb 2024 · SHOC2 acts as a strong synthetic lethal interactor with MEK inhibitors in multiple KRAS cancer cell lines. SHOC2 forms a heterotrimeric complex with MRAS and … WebThe extracellular signal-regulated kinase (ERK1/2) cascade regulates a myriad of functions in multicellular organisms. Scaffold proteins provide critical spatial and temporal control … nurse giving shot image

SHOC2 phosphatase-dependent RAF dimerization …

Category:The function of Shoc2: A scaffold and beyond - Taylor & Francis

Tags:Shoc2 inhibitor

Shoc2 inhibitor

Alinah Sum-Ping Leung - 英國倫敦大學學院 - London Area, United …

Web26 Oct 2024 · These data indicate that SHOC2 may be a therapeutic target for patients with NSCLC or a biomarker to predict sensitivity to EGFR-TKI therapy in EGFR mutation-positive … WebSHOC2 is a scaffold protein composed of leucine-rich repeats and is a positive regulator of the RAS-MAPK pathway ( Simanshu et al., 2024 ). SHOC2 binds directly to MRAS and the …

Shoc2 inhibitor

Did you know?

WebSHOC2 was recently identified as one of five genes necessary for proliferation of RAS mutant but not RAS–wild-type acute myeloid leukemia cell lines and in a screen to … WebSHOC2 has been shown to interact with the catalytic phosphatase subunit PP1C(PMID 16630891) and MRAS as well as canonical RAS isoforms (H/K/NRAS)(PMID 35768504, …

Web17 Jun 2024 · With its diverse function in disease progression and prognosis, Shoc2 presents an exciting possibility as a therapeutic target. A recent study by Sulahian et al. in … Web24 Jun 2024 · Original Article Jun 24, 2024. Acquired Resistance to KRASG12C Inhibition in Cancer. M. M. Awad and Others. A study involving 38 patients who initially had a response to adagrasib or who had a ...

Web24 Jan 2024 · Human SHOC2 is a scaffold protein that accelerates ERK1/2 signal transduction, and SHOC2 is highly conserved from parasites to mammals ; ... Influence of …

Web1 Oct 2024 · In particular, we demonstrate that knockout, suppression, or degradation of SHOC2, a positive regulator of MAPK signaling, specifically cooperated with MEK …

Webefficacy of current ERK pathway inhibitors. The SHOC2-MRAS-PP1 phosphatase complex (SHOC2 complex) plays a key role in ERK pathway regulation by dephosphorylating a … nurse giveawaysWeb7 Dec 2012 · SHOC2 was required, at least partially, for the survival of BRAF V600E /NRAS Q61K cells in the presence of PLX4720. These data provide novel insight into a … nist 800-53 security control familiesWebConclusion: NRAS mutations in mutant BRAF cells alter RAF isoform and SHOC2 usage in the presence of RAF inhibitor. Significance: These studies delineate mechanisms mediating RAF inhibitor resistance in mutant BRAF cells. ERK1/2 signaling is frequently dysregulated in tumors through BRAF mutation. Targeting mutant BRAF with vemu- nist 800 63 password expirationWebData show that both Shoc2 and HUWE1 are necessary to control the levels and ubiquitination of the Shoc2 signaling partner, RAF-1. Both MRAS and SHOC2 play a key … nist 800-63 level 4 authenticationWeb2 Dec 2024 · Targeting SHOC2 with pan-RAF inhibitors (pan-RAFis) in combination with MEKi was effective in parental LGSOC cell lines, in MEKi-resistant derivatives, in primary ascites cultures from patients with LGSOC, and in LGSOC (cell line-derived and patient-derived) xenograft mouse models. We found that the combination of pan-RAFi with MEKi ... nist 800 53 software developmentWeb24 Jun 2024 · Original Article Jun 24, 2024. Acquired Resistance to KRASG12C Inhibition in Cancer. M. M. Awad and Others. A study involving 38 patients who initially had a response … nist 800 53 technical control familiesWebBALVERSA (erdafitinib) is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic … nist 800-53 system and information integrity